Cagatay Arslan

Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial.

M. Oya, N. Mehra, C. Poehlein, 2023, The Lancet. Oncology.

Screening colonoscopy participation in Turkish colorectal cancer patients and their first degree relatives.

S. Kılıçkap, Cagatay Arslan, Dorina Rama, 2012, Asian Pacific journal of cancer prevention : APJCP.

Adrenocortical Cancer in the Real World: A Comprehensive Analysis of Clinical Features and Management from the Turkish Oncology Group (TOG).

U. Kefeli, S. Kılıçkap, P. Yumuk, 2024, Clinical genitourinary cancer.

The safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter real-world study from Turkey

U. Demirci, O. Dizdar, E. Goker, 2023, Medicine.